NEUREN PHARMACEUTICALS LIMITED
ASX:NEUPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 97.9% of what they think they own, once every option and right converts.
2% of shares in the money
NEUREN PHARMACEUTICALS LIMITED's ordinary share count decreased by 0.8% between June 2024 and June 2026, its latest share-count filing, to 127M shares. The company has not raised capital through any cash placement, rights issue or share purchase plan in the 24-month window. Options and rights on issue could convert into 3M new shares, representing a 2.2% overhang of current shares, of which 2.0% are in the money at the current share price; the nearest expiry is February 2029. The company's latest cash report is a half-year/annual report, not a quarterly report, and shows non-negative net cash flow, so no funding-runway figure applies. No proposed securities issues are pending.
Quick answers · 3
How much placement capacity does NEU have left?
None of the 15% placement capacity counted as used in the last 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
When do NEU's options expire?
Unexercised options and rights equal 2.2% of Neuren Pharmaceuticals's shares on issue; the nearest expiry is Feb 2029.
How much has NEU's share count grown?
Neuren Pharmaceuticals has 126.8M shares on issue as at 28 Oct 2026, down 0.8% over 24 months according to its Appendix 2A filings.
Shares on issue — last 2 years
Cumulative figures as stated by the company on its daily notice. Latest notice
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 18 June 2026 | 2A · quoted issue | NEU : ORDINARY FULLY PAID | 126.8M | Appendix 2A |
| 1 June 2026 | 3G · unquoted | NEU : ORDINARY FULLY PAID | 126.4M | Appendix 3G |
| 1 June 2026 | 3H · cancellation | NEU : ORDINARY FULLY PAID | 126.3M | Appendix 3H |
| 12 May 2026 | 3H · cancellation | NEU : ORDINARY FULLY PAID | 126.4M | Appendix 3H |
| 10 Apr 2026 | 3H · cancellation | NEU : ORDINARY FULLY PAID | 126.5M | Appendix 3H |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
At $18.95 today, 2.4M securities are in the money (1.9% of shares on issue). No more priced supply until 1.25× today’s price, which takes it to 2.7M (2.2% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| NEUAAC | Options | Price-triggered | $23.09 | 7 Feb 2029 | 260k | Filing |
| NEUAA | Options | Price-triggered | $12.91 | 23 May 2030 | 1.8M | Filing |
| NEUAB | Options | Price-triggered | $14.10 | 9 July 2030 | 210k | Filing |
| NEUAAD | Options | Price-triggered | $19.63 | 19 Sept 2030 | 115k | Filing |
| NEUAD | Options | Price-triggered | $13.62 | 27 May 2031 | 360k | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 5 Mar 2026 | Joseph Basile | Buy on-market | 12k | — | — | $152k | 3Y notice |
| 8 Sept 2025 | Jonathan Pilcher | Sell on-market | — | — | — | — | 3Y notice |
| 22 July 2025 | Jonathan Pilcher | Buy | 1.5M | — | — | $2.8M | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.